LNWTC
KZIA

Laird Norton Wetherby Trust Company’s Kazia Therapeutics KZIA Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Buy
12,900
+500
+4% +$6.09K ﹤0.01% 1009
2026
Q1 		$92.3K Buy
+12,400
New +$86.3K ﹤0.01% 978

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Laird Norton Wetherby Trust Company's KZIA Position: Q2 2026 in Review

Laird Norton Wetherby Trust Company increased its Kazia Therapeutics (KZIA) stake by 4% in Q2 2026, buying an estimated $6.09K and bringing the position to 12,900 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #1009.

Laird Norton Wetherby Trust Company first reported a position in KZIA in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Laird Norton Wetherby Trust Company held 12,900 shares of Kazia Therapeutics worth $182K as of Q2 2026.
  • Laird Norton Wetherby Trust Company bought 500 Kazia Therapeutics shares in Q2 2026, an estimated $6.09K.
  • Kazia Therapeutics made up ﹤0.01% of Laird Norton Wetherby Trust Company's portfolio in Q2 2026, its #1009 holding.
  • Laird Norton Wetherby Trust Company first reported a position in Kazia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2026, filed 14 Aug 2026.